Skip to content
Triangle logo TriangleGet started
← Study library

NCT01769222 · REGISTRY CONDITION SEARCH

Ipilimumab and Local Radiation for Selected Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
TERMINATED
Registry last update
2024-01-24

This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. * The phase 1 component ("safety") of this study is ipilimumab 25 mg monotherapy. * The phase 2 component ("treatment-escalation") of this study is ipilimumab 25 mg plus radiation combination therapy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Dose-limiting Toxicity

→

outcome · POSTED

Immune Response (Phase 2 Only)

→

outcome · POSTED

Immune Response (Phase 2 Only)

→

outcome · POSTED

Response Rate (Phase 2 Only)

→

outcome · POSTED

Overall Survival (Phase 2 Only)

→

outcome · POSTED

Duration of Response (Phase 2 Only)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Willing and able to give written informed consent * Before any study procedures are performed, subjects (or their legally acceptable representatives) will have the details of the study described to them, and they will be given a written informed consent document to read; then, if subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of study personnel * Histologically confirmed malignancy * In Phase 1, histologically confirmed melanoma. * In Phase 2, histologically confirmed melanoma, non-Hodgkin lymphoma, or colorectal carcinoma * Must have failed at least 1 systemic therapy or be intolerant to at least one prior systemic treatment * Must have at least 2 lesions of evaluable size by modified World Health Organization (mWHO)/Cheson criteria; 1 of 2 lesions must be amenable to biopsy (core or fine needle aspirate) and intratumoral injection of up to 5 mL (diameter ≥ 10mm) * Subjects with asymptomatic brain metastases are eligible; (systemic steroids should be avoided if possible, or the subject should be stable on the lowest clinically effective dose, as steroids as they may interfere with the activity of ipilimumab if administered at the time of the first ipilimumab dose) * Must be at least 28 days since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Life expectancy of ≥ 16 weeks * Subjects must have baseline (screening/baseline) radiographic images, (e.g. brain, chest, abdomen, pelvis, and bone scans with specific imaging tests to be determined by the attending physician) within 6 weeks of initiation of ipilimumab * White blood cell (WBC) ≥ 2000/uL (\~2 x 10\^9/L) * Absolute neutrophil count (ANC) ≥ 1000/uL (\~0.5 x 10\^9/L) * Platelets ≥ 75 x 10\^3/uL (\~75 x 10\^9/L) * Hemoglobin ≥ 9 g/dL (may be transfused) * Creatinine ≤ 2.0 x upper limit of normal (ULN) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x ULN for subjects without liver metastasis ≤ 5 times for liver metastases * Bilirubin ≤ 2.0 x ULN (except for subjects with Gilbert's syndrome, who must have a total bilirubin of less than 3.0 mg/dL) * No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized; WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal; post-menopause is defined as: * Amenorrhea ≥ 12 consecutive months without another cause, or * For women with irregular menstrual periods and taking hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level ≥ 35 mIU/mL * Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 72 hours before the start of ipilimumab * Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized Exclusion Criteria: * Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix * Autoimmune disease: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are excluded from this study, as are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[eg, Wegener's Granulomatosis\]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis) * Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea * Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult * Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab) * A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4 inhibitor or agonist * Concomitant therapy with any of the following: interleukin-2 (IL 2), interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids * A history of AEs with prior IL-2 or Interferon will not preclude subjects from entering the current study * Any investigational agents * Immunosuppressive agents (unless required for treating potential AEs) * Chronic systemic corticosteroids (unless required for treating treatment emergent AEs or required for management of signs or symptoms due to brain metastases, upon discussion with Bristol-Myers Squibb \[BMS\] medical monitor) * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious) illness * Women of childbearing potential (WOCBP) who: * Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug, or * Have a positive pregnancy test at baseline, or * Are pregnant or breastfeeding * Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stopped; sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the study
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants receive ipilimumab intratumorally on Day 1
    intervention Names
    1. Biological: Ipilimumab
    label
    Ipilimumab 25 mg (Phase 1)
    type
    EXPERIMENTAL
  2. description
    Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
    intervention Names
    1. Biological: Ipilimumab
    2. Radiation: Radiation therapy
    label
    Ipilimumab 25 mg and radiation therapy (Phase 2)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Ipilimumab 25 mg (Phase 1)
    2. Ipilimumab 25 mg and radiation therapy (Phase 2)
    description
    Given intratumorally
    name
    Ipilimumab
    other Names
    1. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
    2. MDX-010
    3. MDX-CTLA-4
    4. Monoclonal antibody CTLA-4
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Ipilimumab 25 mg and radiation therapy (Phase 2)
    description
    Undergo local radiation therapy, 10 Gy x 3 fractions
    name
    Radiation therapy
    other Names
    1. Irradiation
    2. Radiotherapy
    3. Therapy, radiation
    type
    RADIATION
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
intervention Model Description
Phase 1 ipilimumab 25 mg safety only. Subsequent Phase 2 ipilimumab 25 mg and radiation combination (treatment-escalation) was not conducted.
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
3
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Safety as the percentage of patients in Phase 1 (ipilimumab monotherapy) of the study, who experienced dose-limiting toxicities (DLTs) or serious adverse events (SAEs), using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
    measure
    Dose-limiting Toxicity
    time Frame
    4 weeks
secondary Outcomes
  1. description
    Data will be summarized using proportions with exact 95% confidence intervals, means, standard deviations, and ranges.
    measure
    Immune Response (Phase 2 Only)
    time Frame
    4 weeks
  2. description
    Data will be summarized using proportions with exact 95% confidence intervals, means, standard deviations, and ranges.
    measure
    Immune Response (Phase 2 Only)
    time Frame
    8 weeks
  3. description
    Response rates calculated based on the Response Evaluation Criteria in Solid Tumors (RECIST)/RECIST Immunotherapy and Cheson criteria (Phase 2 only). Response rate data will be summarized using proportions with exact 95% confidence intervals, means, standard deviations, and ranges.
    measure
    Response Rate (Phase 2 Only)
    time Frame
    8 weeks
  4. description
    Data will be summarized using Kaplan-Meier estimates for time to event data.
    measure
    Overall Survival (Phase 2 Only)
    time Frame
    Up to 5 years
  5. description
    Data will be summarized using Kaplan-Meier estimates for time to event data.
    measure
    Duration of Response (Phase 2 Only)
    time Frame
    Up to 5 years
Full study description
brief Summary
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. * The phase 1 component ("safety") of this study is ipilimumab 25 mg monotherapy. * The phase 2 component ("treatment-escalation") of this study is ipilimumab 25 mg plus radiation combination therapy.
detailed Description
PRIMARY OBJECTIVES: 1\. To assess the safety of combining intratumoral anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immunotherapy with local radiation therapy in patients with melanoma, non-Hodgkin lymphoma, and colorectal carcinoma with a monotherapy ipilimumab safety lead-in. SECONDARY OBJECTIVES: 1. To assess the induction of an anti-tumor immune responses using laboratory correlative studies. 2. To determine tumor response rates and duration of response at unirradiated tumor sites in patients with advanced malignancies. 3. To identify putative immunologic biomarkers of tumor response. OUTLINE: This is a phase I safety study of ipilimumab monotherapy, followed by a phase 2 study. Only a few subjects participated in the phase 1 portion of this study. The phase 2 treatment-escalation portion of this study (ipilimumab plus radiation combination therapy) was not conducted. Patients receive ipilimumab intratumorally on day 1 and undergo local radiation therapy within 48 hours for at least 3 fractions. After completion of study treatment, patients are followed up at 4 and 8 weeks, and then every 24 weeks for 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-44ebb06ce37034a3936e
      requested nct id
      NCT01769222
      primary nct id
      NCT01769222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      payload sha256
      3f77b995daaf1c493ffc9d62ec872aee36bfb93538f9ed9263671d9da6767632
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-44ebb06ce37034a3936e
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01769222
      occurrences
      1. context exact
        NCT01769222
        end
        11
        exact text
        NCT01769222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Testicular Cancer
      query disease state id
      ds-testicular-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      source json pointer
      /studies/6/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c2af92846b7ba4af92c94ac4177cf2870904fe7a39a54b256ebe0c9cf2e68bf2
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6dc44b8c688c930e8337
      requested nct id
      NCT01769222
      primary nct id
      NCT01769222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      b09d6dfbcc8ff895c155f438f032181ed07fa0d42bb0bdd55b47608f58910ca5
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6dc44b8c688c930e8337
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01769222
      occurrences
      1. context exact
        NCT01769222
        end
        11
        exact text
        NCT01769222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/13/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c2af92846b7ba4af92c94ac4177cf2870904fe7a39a54b256ebe0c9cf2e68bf2
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7caf830916a32fe5b018
      requested nct id
      NCT01769222
      primary nct id
      NCT01769222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      payload sha256
      fc5d4683cfcd5c1c940aa19c5f13bd6f6ccd72784530211ceeb5b276ed0141ab
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7caf830916a32fe5b018
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01769222
      occurrences
      1. context exact
        NCT01769222
        end
        11
        exact text
        NCT01769222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hairy Cell Leukemia
      query disease state id
      ds-hairy-cell-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      source json pointer
      /studies/5/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c2af92846b7ba4af92c94ac4177cf2870904fe7a39a54b256ebe0c9cf2e68bf2
    4. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-8e94ffe7cafdd5acb0fa
      requested nct id
      NCT01769222
      primary nct id
      NCT01769222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      daa1f3769e9c3bff5db0133bc7a095ae16097011dabe228efd48f073241a1707
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-8e94ffe7cafdd5acb0fa
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01769222
      occurrences
      1. context exact
        NCT01769222
        end
        11
        exact text
        NCT01769222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/17/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c2af92846b7ba4af92c94ac4177cf2870904fe7a39a54b256ebe0c9cf2e68bf2
    5. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-9c368be746d8750c4f82
      requested nct id
      NCT01769222
      primary nct id
      NCT01769222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      3481d29753f564f15799629993beb3d6539af41ce604c9e4867b360b1e0b1a6a
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-9c368be746d8750c4f82
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01769222
      occurrences
      1. context exact
        NCT01769222
        end
        11
        exact text
        NCT01769222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/138/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c2af92846b7ba4af92c94ac4177cf2870904fe7a39a54b256ebe0c9cf2e68bf2

    Preserved source evidence · Not medical advice